Reproductive ageing, sex steroids and depression

Journal of the British Menopause Society

Volumn 12, Issue 4, 2006, Pages 178-185

  Schmidt, Peter J ^a   Rubinow, David R ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; Estradiol; Menopause; Perimenopause; Reproductive ageing

Indexed keywords

ANTIDEPRESSANT AGENT; ESTRADIOL; ESTROGEN; GESTAGEN; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE;

AGING; CLIMACTERIUM; CLINICAL TRIAL; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISABILITY; DISEASE ASSOCIATION; DRUG EFFICACY; DYSPHORIA; HORMONAL THERAPY; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; LONGITUDINAL STUDY; MAJOR DEPRESSION; MENOPAUSAL SYNDROME; MENOPAUSE; META ANALYSIS; MORBIDITY; NONHUMAN; PREVALENCE; REPRODUCTIVE HEALTH; REVIEW; RISK FACTOR; SENESCENCE; SYSTEMATIC REVIEW;

AFFECT; DEPRESSION; ESTRADIOL; FEMALE; GONADAL STEROID HORMONES; HUMANS; PERIMENOPAUSE;

EID: 33845901241     PISSN: 13621807     EISSN: 17404568     Source Type: Journal    
DOI: 10.1258/136218006779160454     Document Type: Review

References (117)

1. Wassertheil-Smoller S, Shumaker S, Ockene J, et al. Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI). Arch Intern Med 2004;164: 289-98
2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
3. Kessler RC, Zhao S, Blazer DG, Swartz M. Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey.J Affective Disord 1997;45:19-30
4. Lopez AD, Murray CCJL. The global burden of disease, 1990-2020. Nature Med 1998;4:1241-3
5. Judd LL, Rapaport MH, Paulus MP, Brown JL. Subsyndromal symptomatic depression: a new mood disorder? J Clin Psychiatry 1994;55:18-28
6. Fava M, Kendler KS. Major depressive disorder. Neuron 2000; 28:335-41
7. Trivedi MH, Rush AJ, Wisniewski SR, et al Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice Am J Psychiatry 2006;163:28-40
8. Trivedi MH, Fava M, Wisniewski SR, et al, Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-52
9. Rubinow DR. Treatment strategies after SSRI failure - good news and bad news. N Engl J Med 2006;354:1305-7
10. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-42
11. Spijker J, de Graaf R, Bijl RV, Beekman ATF, Ormel J, Nolen WA. Duration of major depressive episodes in the general population: results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Br J Psychiatry 2002;181:208-13
12. Montgomery JC, Brincat M, Tapp A, et al, Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet 1987;329:297-9
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). Washington, DC: APA, 1994
14. Spitzer RL, Williams JB, Gibbon M, First MB. Structured Clinical Interview for DSM-III-R, patient edition New York: Biometrics Research Department, New York State Psychiatric Institute, 1990
15. Roberts RE, Vernon SW. The Center for Epidemiologic Studies Depression Scale: its use in a community sample. Am J Psychiatry 1983;140:41-6
16. FFreeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004;61:62-70
17. McKinlay JB, McKinlay SM, Brambilla D, The relative contributions of endocrine changes and social circumstances to depression in mid-aged women. J Health Soc Behav 1987;28: 345-63
18. Fugate Woods N, Mariella A, Sullivan Mitchell E. Patterns of depressed mood across the menopausal transition: approaches to studying patterns in longitudinal data. Acta Obstet Gynecol Scand 2002;81:623-32
19. Frasure-Smith N, Lesperance F, Talajic M, Depression and 18-month prognosis after myocardial infarction. Circulation 1995;91:999-1005
20. Schmidt PJ, Rubinow DR. Mood and the perimenopause. Contemp Ob Gyn 1994;39:168-75
21. Weissman MM, Leaf PJ, Tischler GL, et al. Affective disorders in five United States communities. Psychol Med 1988;16:141-53
22. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J Affective Disord 1993;29:85-96
23. Kaufert PA, Gilbert P, Tate R. The Manitoba project: a: re-examination of the link between menopause and depression. Maturitas 1992;14:143-55
24. Avis NE, Brambilla D, McKinlay SM, Vass K, A longitudinal analysis of the association between menopause and depression: results from the Massachusetts Women's Health Study. Ann Epidemiol 1994;4:214-20
25. Matthews KA, Wing RR, Kuller LH, et al. Influences of natural menopause on psychological characteristics and symptoms of middle-aged healthy women. J Consult Clin Psychol 1990;58: 345-51
26. Holte A. Influences of natural menopause on health complaints: a prospective study of healthy Norwegian women. Maturitas 1992;14:127-41
27. Maartens LW, Leusink GL, Knottnerus JA, Smeets CG, Pop VJ. Climacteric complaints in the community. Fam Pract 2001; 19:189-94
28. den Tonkelaar I, Broekmans FJ, de Boer EJ, et al. The stages of reproductive aging workshop (letter to the editor). Menopause 2002;9:463-4
29. Hardy R, Kuh D. Change in psychological and vasomotor symptom reporting during the menopause. Soc Sci Med 2002; 55:1975-88
30. Dennerstein L, Lehert P, Burger H, Dudley E. Mood and the menopausal transition. J Nerv Ment Dis 1999;187:685-91
31. Hunter M. The South-East England longitudinal study of the climacteric and postmenopause. Maturitas 1992;14:117-26
32. O'Connor VM, Del Mar CB, Sheehan M, Siskind V, Fox-Young S, Cragg C. Do psycho-social factors contribute more to symptom reporting by middle-aged women than hormonal status? Maturitas 1995;20:63-9
33. Bromberger JT, Meyer PM, Kravitz HM, et al. Psychologic distress and natural menopause: a multiethnic community study. Am J Public Health 2001;91:1435-42
34. Maartens LWF, Knottnerus JA, Pop VJ. Menopausal transition and increased depressive symptomatology: A community based prospective study. Maturitas 2002;42:195-200
35. Bromberger JT, Assmann SF, Avis NE, Schocken M, Kravitz HM, Cordal A. Persistent mood symptoms in a multiethnic community cohort of pre- and perimenopausal women. Am J Epidemiol 2003;158:347-56
36. Stewart DE, Boydell K, Derzko C, Marshall V. Psychologic distress during the menopausal years in women attending a menopause clinic. Int J Psychiatry Med 1992;22:213-20
37. Dennerstein L, Smith AMA, Morse C, et al. Menopausal symptoms in Australian women. Med J Aust 1993;159:232-6
38. Hay AG, Bancroft J, Johnstone EC. Affective symptoms in women attending a menopause clinic. Br J Psychiatry 1994;164: 513-16
39. Spitzer RL, Williams JBW, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care: the PRIME-MD 1000 study. JAMA 1994;272:1749-56
40. Schmidt PJ, Haq NA, Rubinow DR. A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women. Am J Psychiatry 2004;161: 2238-44
41. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition. The Harvard study of moods and cycles. Arch Gen Psychiatry 2006;63:385-90
42. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006; 63:375-82
43. Santoro N, Brown JR, Adel T, Skurnick JR. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996;81:1495-501
44. Burger HU, Dudley EC, Hopper JL, et al. The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. J Clin Endocrinol Metab 1995;80: 3537-45
45. Woolley CS, Schwartzkroin PA. Hormonal effects on the brain. Epilepsia 1998;39:S2-8
46. McEwen BS, Alves SE, Bulloch K, Weiland NO. Ovarian steroids and the brain: implications for cognition and aging. Neurology 19917;48 (suppl 7):S8-15
47. Rachman IM, Unnerstall JR, Pfaff DW, Cohen RS. Estrogen alters behavior and forebrain c-fos expression in ovariectomized rats subjected to the forced swim test. Proc Natl Acad Sci USA 1998;95:13941-6
48. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry 1998;44:839-50
49. Pecins-Thompson M, Brown NA, Bethea CL. Regulation of serotonin re-uptake transporter mRNA expression by ovarian steroids in rhesus macaques. Brain Res Mol Brain Res 1998;53: 120-9
50. 1A receptors in hippocampal membranes from ovariectomized rats: functional and binding studies. Brain Res 1990;518:287-91
51. 1A receptor mRNA in female rat brain. Abstr Soc Neurosci 1997;23:1501
52. Sohrabji F, Miranda RC, Toran-Allerand CU. Estrogen differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. J Neurosci 1994;14:459-71
53. Zhou Y, Watters JJ, Dorsa DM. Estrogen rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain. Endocrinology 1996;137:2163-6
54. Sohrabji F, Greene LA, Miranda RC, Toran-Allerand CD. Reciprocal regulation of estrogen and NGF receptors by their ligands in PC12 cells. J Neurobiol 1994;25:974-88
55. Rocha BA, Fleischer R, Schaeffer JM, Rohrer SP, Hickey GJ. 17 β-estradiol-induced antideprossant-like effect in the forced swim test is absent in estrogen receptor-β knockout (BERKO) mice. Psychopharmacology 2005;179:637-43
56. Walf AA, Rhodes ME, Frye CA. Antidepressant effects of ERß-selective estrogen receptor modulators in the forced swim test. Pharmacol Biochem Behav 2004;78:523-9
57. Lund TD, Rovis T, Chung WCJ, Handa RJ. Novel actions of estrogen receptor-β on anxiety-related behaviors. Endocrinology 2005; 146:797-807.
58. Daly RC, Danaceau MA, Rubinow DR, Schmidt PJ. Concordant restoration of ovarian function and mood in perimenopausal depression. Am J Psychiatry 2003;160:1842-6
59. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000;183:414-20
60. Soares CD, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001;58:529-34
61. Steingold KA, Laufer L, Chethowski RJ, et al. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab, 1985;61:627-32
62. Brincat M, Studd JWW, O'Dowd T, et al. Subcutaneous hormone implants for the control of climacteric symptoms: a prospective study, Lancet 1984,323:16-18
63. Ditkoff EC, Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 1991;78:991-5
64. Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985;151:153-60
65. Brambilla F, Maggioni M, Ferrari E, Scarone S, Catalano M. Tonic and dynamic gonadotropin secretion in depressive and normothymic phases of affective disorders. Psychiatry Res 1990;32:229-39
66. Amsterdam JD, Winokur A, Lucki I, Snyder P. Neuroendocrine regulation in depressed postmenopausal women and healthy subjects. Acta Psychiatr Scand 1983;67:43-9
67. Altman N, Sachar EJ, Gruen PH, Halpern FS, Eto S. Reduced plasma LH concentration in postmenopausal depressed women. Psychosom Med 1975;37:274-6
68. Guicheney V, Leger D. Barrat J, et al. Platelet serotonin content and plasma tryptophan in peri- and postmenopausal women: variations with plasma ocstiogen levels and depressive symptoms. Eur J Clin Invest 1988;18:297-304
69. Ballinger S. Stress as a factor in lowered estrogen-levels in the early postmenopause. Ann N Y Acad Sci 1990;592:95-113.
70. Huerta R, Mena A, Malacara JM, Diaz de Leon J. Symptoms at perimenopausal period: its association with attitudes toward sexuality, life-style, family function, and FSH levels. Psychoneuroendocrinology 1995;20:135-48
71. Saletu B, Brandstatter N, Metka M, et al. Hormonal, syndromal and EEG mapping studies in menopausal syndrome patients with and without depression as compared with controls. Maturitas 1996;13:91-105
72. Barrett-Connor E, von Muhlen D, Laughlin GA, Kripke A. Endogenous levels of dehydroepiandrostetone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo study. J Am Geriatr Soc 1999;47:685-91
73. Cawood EHH, Bancroft J. Steroid hormones, the menopause, sexuality and well-being of women. Psychol Med 1996;26:925-36
74. Schmidt PJ, Murphy JH, Haq N, Danaceau MA, Simpson St Clair L. Basal plasma hormone levels in depressed perimenopausal women. Psychoneuroendocrinology 2002;27:907-20
75. Matthews KA. Myths and realities of the menopause. Psychosom Med 1992;54:1-9
76. A receptor. Brain Res 1990;526:143-6
77. Compagnone NA, Mellon SH. Dehydroepiandrosterone: a potential signalling molecule for neocortical organization during development. Proc Natl Acad Sci USA 1998;95:4678-83
78. Baulieu E-E, Robel P. Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) as neuroactive neurosteroids. Proc Natl Acad Sci USA 1998,95:4089-91
79. Robel P, Baulieu E-E. Neurosteroids, biosynthesis and function. Trends Endocrinol Metab 1994;5:1-8
80. Zwain IH, Yen SSC. Dehydroepiandrosterone: biosynthesis and metabolism in the brain. Endocrinology 1999;140:880-7
81. Morales AJ, Nolan JJ, Nelson JC, Yen SSC. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78:1360-7
82. Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999;156:646-9
83. Wolkowitz OM, Reus VI, Roberts E, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry 1997; 41:311-18
84. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of mid-life dysthymia. Biol Psychiatry 1999;45:1533-41
85. Wolt OT, Neumann O, Hellhammer DH, et al. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab 1997;82:2363-7
86. Goodyer IM, Herbert J, Altham PME, Pearson J, Secher SM, Shiers HM. Adrenal secretion during major depression in 8- to 16-year-olds, I. Altered diurnal rhythms in salivary cortisol and dehydroepiandrosterone (DHEA) at presentation. Psychol Med 1996;26:245-56
87. Goodyer IM, Herbert J, Altham PME. Adrenal steroid secretion and major depression in 8- to 16-year-olds, III. Influence of cortisol/DHEA ratio at presentation on subsequent rates of disappointing life events and persistent major depression. Psychol Med 1998;28:265-73
88. Ferrari E, Locatelli M, Arcaini A, et al. Chronobiological study of some neuroendocrine features of major depression in elderly people. 79th Annual Meeting of the Endocrinology Society, 1997: abstract
89. Heuser I, Deuschle M, Luppa P, Schweiger U, Standhardt H, Weber B. Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients. J Clin Endocrinol Metab 1998;83:3130-3
90. Laughlin GA, Barrett-Connor E. Sexual dimorphism in the influence of advanced aging on adrenal hormone levels: the Rancho Bernardo study. J Clin Endocrinol Metab 2000;85:3561-8
91. Cumming DC, Rebar RW, Hopper BR, Yen SSC. Evidence for an influence of the ovary on circulating dehydroepiandrosterone sulfate levels. J Clin Endocrinol Metab 1982;54: 1069-71
92. Gray A, Feldman HA, McKinlay JB, Longcope A. Age, disease and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endrocrinol Metab 1991;73:1016-23
93. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984;59:551-5
94. Orentreich N, Brind JL, Vogelman JH, Andres R, Baldwin H. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 1992;75:1002-4
95. Belanger A, Candas B, Dupont A, et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab 1994;79:1086-90
96. Coope J. Is oestrogen therapy effective in the treatment of menopausal depression? J R Coll Gen Pract 1981;31:134-40
97. Campbell S. Double-blind psychometric studies on the effects of natural estrogens on post-menopausal women. In: Campbell S, ed. The Management of the Menopause and Postmenopausal Years. Lancaster: MTP Press Ltd, 1976: 149-58
98. George GCW, Utian WH, Beumont PJV, Beardwood CJ. Effect of exogenous oestrogens on minor psychiatric symptoms in postmenopausal women. S Afr Med J 1973;47:2387-8
99. Saletu B, Brandstatter N, Metka M, et al. Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression. Psychopharmacology 1995;122:321-9
100. Sherwin BB. Affective changes with estrogen and androgen replacement therapy in surgically menopausal women. J Affective Disord 1988;14:177-87
101. Klaiber EE, Broverman DM, Vogel W, Kobayashi Y. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry 1979;36:550-4
102. Zweifel JE, O'Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997;22:189-212
103. Morrison MF, Kallan MJ, Ten Have T, Katz I, Tweedy K, Battistini M. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry 2004;55:406-12
104. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders: results from the PRIME-MD 1000 study. JAMA 1995;274:1511-17
105. Appleby L, Montgomery J, Studd J. Oestrogens and affective disorders. In: Studd J, ed. Progress in Obstetrics and Gynaecology. Edinburgh: Churchill Livingstone, 1981: 289-302
106. Amsterdam J, Garcia-Espana F, Fawcett J, et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affective Disord 1999;55:11-17
107. Schneider LS, Small GW, Hamilton SH, Bystritsky A, Nemeroff CB, Meyers BS. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Am J Geriatr Psychiatry 1997;5:97-106
108. Schneider LS, Small GW, Clary CM. Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. Am J Geriatr Psychiatry 2001;9:393-9
109. Cohen LS, Soares CN, Poitras JR, Prouty J, Alexander AB, Shifren JL. Short-term use of estradiol for depression in perimenopausal and postmenopausal women: a preliminary report. Am J Psychiatry 2003;160:1519-22
110. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
111. Shumaker SA, Legault C, Kuller L, et al, Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative memory study. JAMA 2004;291:2947-58
112. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative memory study. JAMA 2004;291:2959-68
113. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative memory study: a randomized controlled trial. JAMA 2003;289:2651-62
114. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
115. Fava M, Abraham M, Alpert J, Nierenberg AA, Pava JA, Rosenbaum JF. Gender differences in axis I comorbidity among depressed outpatients. J Affective Disord 1996;38:129-33
116. Rubinow DR, Schmidt PJ. Hormone replacement therapy: the last waltz or a new step? SAGE Crossroads. Available at www.sagecrossroads.net/public/ news. Accessed 3 August 2004
117. Naftolin F, Taylor HS, Karas R, et al, The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 2004,81:1498-501